2024
Clinician perspectives regarding CYP2C19 genotype testing in patients with critical limb ischemia: A Delphi approach.
Regan C, Scierka L, Dardik A, Tonnessen B, Iyad Ochoa Chaar C, Ionescu C, Aboian E, Cardella J, Nassiri N, Guzman R, Attaran R, Nagpal S, Shah S, Smolderen K, Mena-Hurtado C. Clinician perspectives regarding CYP2C19 genotype testing in patients with critical limb ischemia: A Delphi approach. Vascular 2024, 17085381241246318. PMID: 38669051, DOI: 10.1177/17085381241246318.Peer-Reviewed Original ResearchDual antiplatelet therapyPeripheral arterial diseaseCYP2C19 testingCYP2C19 mutationsHeterogeneity of treatment effectsPeripheral vascular interventionsConsensus statementKnowledge questionsAntiplatelet therapyGenetic testingVascular surgeryAcademic health systemBarriers to implementationInterquartile rangeCYP2C19 genotype testingVascular diseaseInterventional cardiologyModified Delphi methodPatient's metabolic statusManagement of patientsCritical limb ischemiaPerceived barriersPeripheral vascular diseaseArterial vascular diseaseClinician perspectives
2008
Periprocedural Drug Therapy in Carotid Artery Stenting: The Need for More Evidence
Gortler D, Schlösser FJ, Muhs BE, Nelson MA, Dardik† A. Periprocedural Drug Therapy in Carotid Artery Stenting: The Need for More Evidence. Vascular 2008, 16: 303-309. PMID: 19344586, DOI: 10.2310/6670.2008.00081.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCarotid endarterectomyLarge prospective cohort studyDual antiplatelet therapyProspective cohort studyCarotid artery stentingCohort studyArtery stentingPeriprocedural settingDrug therapyPharmacologic agentsCarotid arteryHigh riskPatient careTherapyOptimal outcomesRegimenGood validityPatientsMore evidenceOutcomesOptimal timeClopidogrelEndarterectomyMedicationsStenting